ImmunityBio (IBRX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec16

ImmunityBio Announces ANKTIVA in Combination with BCG Achieves 96% Three-Year Survival Rate for Bladder Cancer

14:01

Dec12

ImmunityBio's Anktiva in combination with BCG receives conditional market authorization recommendation from EMA

17:05

Dec2

ImmunityBio Inc. to Attend Piper Sandler 37th Annual Healthcare Conference

23:39

Nov6

ImmunityBio released FY2025 9 Months earnings on November 5 (EST), actual revenue USD 75M, actual EPS USD -0.3272

04:00

ImmunityBio released FY2025 Q3 earnings on November 5, 2025 (EST), actual revenue USD 32.06 M (forecast USD 31.88 M), actual EPS USD -0.071 (forecast USD -0.108)

04:00

Nov5

ImmunityBio Reports Sales Growth and Launches Glioblastoma Clinical Trial

03:16

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 32.06 M, Net Income -67.25 M, EPS -0.071

Aug5

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 26.43 M, Net Income -92.56 M, EPS -0.1042

May12

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 16.52 M, Net Income -129.65 M, EPS -0.1519

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More